FY2030 Earnings Estimate for JSPR Issued By HC Wainwright

Jasper Therapeutics, Inc. (NASDAQ:JSPR) – Analysts at HC Wainwright issued their FY2030 earnings per share (EPS) estimates for shares of Jasper Therapeutics in a research note issued on Tuesday, March 31st. HC Wainwright analyst E. Bodnar expects that the company will post earnings of ($0.75) per share for the year. The consensus estimate for Jasper Therapeutics’ current full-year earnings is ($4.47) per share.

Other equities analysts have also issued reports about the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Jasper Therapeutics in a research note on Thursday, January 22nd. UBS Group began coverage on shares of Jasper Therapeutics in a report on Monday, March 23rd. They issued a “neutral” rating for the company. Finally, Rodman & Renshaw started coverage on shares of Jasper Therapeutics in a research report on Tuesday, January 13th. They issued a “buy” rating and a $17.00 target price on the stock. Six research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $19.88.

Jasper Therapeutics Stock Down 8.7%

JSPR stock opened at $0.80 on Wednesday. The business has a 50 day moving average price of $1.30 and a 200 day moving average price of $1.76. The stock has a market cap of $22.38 million, a price-to-earnings ratio of -0.17 and a beta of 3.20. Jasper Therapeutics has a fifty-two week low of $0.80 and a fifty-two week high of $7.19.

Jasper Therapeutics (NASDAQ:JSPR) last released its quarterly earnings data on Monday, March 30th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.47.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of JSPR. Acadian Asset Management LLC acquired a new stake in shares of Jasper Therapeutics during the first quarter worth about $46,000. Marex Group plc purchased a new position in shares of Jasper Therapeutics during the second quarter worth about $74,000. Engineers Gate Manager LP acquired a new position in Jasper Therapeutics in the 2nd quarter valued at about $78,000. Panagora Asset Management Inc. purchased a new stake in Jasper Therapeutics during the 4th quarter valued at approximately $35,000. Finally, Voleon Capital Management LP purchased a new stake in Jasper Therapeutics during the 3rd quarter valued at approximately $50,000. 79.85% of the stock is currently owned by institutional investors and hedge funds.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.